Search
Dirocaftor
go.drugbank.com/drugs/DB16143InvestigationalDirocaftor is under investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis).
Pacibekitug
go.drugbank.com/drugs/DB19307InvestigationalHuman anti-il-6 monoclonal antibody (pf-04236921) is under investigation in clinical trial NCT01405196 (Subcutaneous Treatment in Randomized Subjects to Evaluate Safety and Efficacy in Generalized Lupus
Synonyms: HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY (PF-04236921)VH4367310
go.drugbank.com/drugs/DB33961ExperimentalVH4367310 is under investigation in clinical trial NCT07818915 (A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants).
PF-04991532
go.drugbank.com/drugs/DB11765InvestigationalPF-04991532 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Glucose Metabolism Disorders.
Mineral oil
go.drugbank.com/drugs/DB11057ApprovedInvestigationalVet approvedMineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that ar...
Mixtures: Lubricant PM, retaine PMFecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigational[A259182,L46217,L46222] Although the incidence of CDI has declined and the number of cases requiring hospitalization has been lower over the years, the recurrence of CDI still represents a challenge.
Radium Ra-223
go.drugbank.com/drugs/DB12813InvestigationalRadium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
RR001
go.drugbank.com/drugs/DB17369Investigationalan investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (AD-PC
Nimacimab
go.drugbank.com/drugs/DB15115InvestigationalNimacimab is under investigation in clinical trial NCT03261739 (Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)).
Blinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigational[L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.[A254826]